Skip to main content
Premium Trial:

Request an Annual Quote

Mesa Biotech Awarded $13M in BARDA Funding for Coronavirus, Flu Combo Test

NEW YORK — Mesa Biotech said on Friday that it has received $13 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) for the development of a rapid point-of-care test for SARS-CoV-2 and influenza.

The visually read, PCR-based test will be designed to detect SARS-CoV-2 and influenza types A and B in throat, nasal, or nasopharyngeal swab samples within 30 minutes. It will run on Mesa's handheld Accula Dock system.

In March, Mesa received $561,330 from BARDA to develop and commercialize an Accula-based SARS-CoV-2 test, which received Emergency Use Authorization from the FDA shortly thereafter. The San Diego-based company also has FDA-cleared and CLIA-waived Accula tests for influenza and respiratory syncytial virus.

"The 2020-21 influenza season will pose new challenges to the public health response to the coronavirus pandemic," Mesa Cofounder and Chief Technology Officer Hong Cai said in a statement. "With two viruses that cause respiratory symptoms circulating, physicians and public health officials will need to know whether patients have COVID-19 or influenza to make informed decisions about care and take appropriate actions to minimize the spread of the pathogens."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.